featured
Risk of Malignancies in Patients With Psoriasis Treated With IL-17 and IL-23 Inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of the European Academy of Dermatology and Venereology: JEADV
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Are interleukin 17 and interleukin 23 inhibitors associated with malignancies? - Insights from an international population-based study
J Eur Acad Dermatol Venereol 2023 Sep 20;[EPub Ahead of Print], K Kridin, M Abdelghaffar, N Mruwat, RJ Ludwig, D ThaçiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.